SLC5A2 and chronic kidney disease: Nevertheless, previous clinical studies have provided evidence that SGLT-2 inhibitors can delay the progression of chronic kidney disease (CKD) and can be administered to patients with heart failure or CKD, or at risk for adverse cardiac or renal pathologies12.